A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy
Received 11 March 2006; received in revised form 6 June 2006; accepted 6 June 2006. published online 15 September 2006.
Purpose: This study established a prognostic scoring system for nasopharyngeal carcinoma (NPC), which estimates the probability of locoregional (LR) control following definitive conformal radiotherapy.
Methods and Materials: Patients with nondisseminated NPC at initial presentation (n = 630) were enrolled in this study. All patients had magnetic resonance imaging of the head and neck and were treated with conformal radiotherapy. Among them, 93% had concurrent chemotherapy, and 76% had postradiation chemotherapy. The extent of the primary tumor, age at diagnosis, primary tumor size, tumor and nodal classification, histology, and serum lactate dehydrogenase (LDH) level before treatment were included in the analysis for building a prognostic scoring system. The end point for this study was LR control.
Results: The prognostic score was defined as the number of adverse prognostic factors present at diagnosis. Four factors had similarly independent prognostic effects (hazard ratio, 2.0–2.6): age >40 years, histologic WHO type I-II, serum LDH level ≥410 U/L, and involvement of two or more sites of the following anatomic structures, i.e., sphenoid floor, clivus marrow, clivus cortex, prevertebral muscles, and petrous bone. The score predicted the 5-year probability of LR control as follows: 0 (15% of the patients), 100%; 1 (42% of the patients), 93%; 2 (29% of the patients), 83%; 3 or higher (13% of the patients), 71%.
Conclusion: This scoring system is useful in the decision-making for individual patients and the design of clinical trials to improve LR control for advanced-stage NPC.
⁎Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
†Department of Research, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
‡Department of Radiology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
§Department of Head and Neck Surgery, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
¶Department of Pathology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
∥Department of Medical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
#Department of Radiation Oncology, Duke University, Durham, NC, USA
⁎⁎Department of Medicine, Duke University, Durham, NC, USA
Reprint requests to: Skye H. Cheng, M.D., Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, No. 125, Lih-Der Road, Pei-Tou District, Taipei, Taiwan. Tel: (+886) 2-754-9152, Ext. 310; Fax: (+886) 2-707-9123.
This study was supported by a grant from the National Health Research Institutes of Taiwan (NHRI-EX94-9216BI) and research fund of Koo Foundation Sun Yat-Sen Cancer Center.